Business
Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting
- Early and durable T cell clone expansion correlates with survival - - Pelareorep-induced u...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting- Early and durable T cell clone expansion correlates with survival -- Pelareorep-induced upregulation of pro inflammatory genes was observed in patients who derived clinical benefit -- Pelareorep primes the immune system, supporting combination treatment with checkpoint inhibitors -CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 16, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract highlighting additional immune-based biomarker data used to help predict patient response to pelareorep in combination with checkpoint inhibitor therapy. The abstract was published online as part of the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in the Meeting Proceedings, an online supplement of ASCO's Journal of Clinical Oncology.The abstract, titled, \"Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC),\" describes further immune analysis of the peripheral blood of patients from REO 024, a completed phase 1b study of pelareorep and Keytruda® (pembrolizumab) in combination with chemotherapy in patients with advanced (second-line) pancreatic cancer. A phase 2 trial of pelareorep plus pembrolizumab in advanced PDAC is currently ongoing.\"The gene expression and cytokine data analysis, as well as TCR-sequencing, provides further insight into the immune environment prior to and during treatment with pelareorep and pembrolizumab,\" said Dr. Rita Laeufle, Chief Medical Officer of Oncolytics Biotech. \"These additional findings further highlight pelareorep's ability to create an inflamed phenotype, resulting in a primed immune system that we believe supports combination treatment with immune checkpoint inhibitors. It also builds on our discovery that T cell clonality can serve as a predictive and prognostic biomarker for clinical benefit when used to identify patients who may respond well to this therapeutic combination. This new biomarker data supports the potential selection of patients in future clinical studies, giving these studies a higher likelihood of success.\"Key data and conclusion...